Survodutide vs Retatrutide: Dual vs Triple Agonist

Survodutide and retatrutide are two of the newer incretin compounds studied in research settings. Both add glucagon receptor activity on top of the GLP-1 mechanism that semaglutide made familiar, but they are built differently. Survodutide is a dual agonist. Retatrutide is a triple agonist. That one structural difference drives most of the gap in their trial weight loss numbers and shapes why each is studied for a different primary question.

Both are research compounds, not approved for self-directed human use. Every figure below comes from published clinical trials and is reference information only. Nothing here is dosing guidance, and no peptide here treats or cures anything. Protocol decisions belong with a licensed clinician. For the arithmetic side, the retatrutide calculator handles the unit conversions covered later in this article.

Receptor targets: dual vs triple

This is the core difference between the two molecules, and it explains everything that follows.

• Survodutide is a dual agonist. It activates the GLP-1 receptor and the glucagon receptor.
• Retatrutide is a triple agonist. It activates the GLP-1 receptor, the glucagon receptor, and the GIP receptor.

Both share the glucagon arm, which is what sets this pair apart from the GLP-1-only and GLP-1 plus GIP compounds. Glucagon receptor activity is studied for its effect on energy expenditure and on fat in the liver. Retatrutide adds the GIP receptor on top, the same second incretin target that defines tirzepatide. For the wider family map, see retatrutide vs tirzepatide and semaglutide vs tirzepatide.

Average weight loss in trials

The headline numbers are study population averages at the highest doses tested, not promises. Individual results in any dataset vary widely around the mean, and the two compounds were tested in separate trials with different designs and durations, so this is a loose comparison, not a head-to-head.

• Survodutide: a Phase 2 obesity trial reported roughly 18.7% average body weight reduction at the highest dose over 46 weeks.
• Retatrutide: a Phase 2 obesity trial reported roughly 24.2% average body weight reduction at the highest dose over 48 weeks.
• The gap: about 5.5 percentage points separated the two trial averages, with retatrutide higher.

The glucagon ratio

Both molecules lean on glucagon, but they balance it differently against GLP-1. The ratio matters because glucagon activity is the part researchers tie to energy expenditure and liver fat, while GLP-1 activity drives most of the appetite effect.

• Survodutide is described as a balanced GLP-1 and glucagon dual agonist, with the glucagon arm a central feature of its design rather than a secondary add-on.
• Retatrutide spreads its activity across three receptors, so glucagon is one of three levers rather than half the molecule.

Neither ratio is inherently better. It is a difference in design that researchers study for different endpoints, which is the next point.

The MASLD angle

The glucagon arm is why both compounds appear in liver research. MASLD, metabolic dysfunction-associated steatotic liver disease, is the current name for fat buildup in the liver tied to metabolic factors. Glucagon receptor activity is studied for its effect on hepatic fat, so the dual and triple agonists are both candidates in this space.

• Survodutide has been studied with a primary focus on MASH, the inflammatory form of fatty liver disease, where a Phase 2 trial reported a meaningful share of participants reaching the studied liver endpoint.
• Retatrutide has reported large reductions in measured liver fat in its obesity trial substudies, though its headline program centers on weight and metabolic endpoints rather than liver disease specifically.

The simple framing: survodutide is studied more directly as a liver-disease compound, while retatrutide is studied first for weight with liver fat as a secondary readout. Both are early in the research pipeline, and none of this is a treatment claim.

Worked example: drawing a dose

Once a vial is reconstituted, the syringe units depend on concentration, not on which peptide it is. The arithmetic is identical for survodutide, retatrutide, or any other lyophilized compound.

1. Take a 10 mg vial and add 2 mL of bacteriostatic water. Concentration is 10 mg / 2 mL = 5 mg/mL.
2. For a 1 mg target: 1 mg / 5 mg/mL = 0.2 mL = 20 units on a U-100 insulin syringe.
3. For a 2 mg target from the same vial: 2 / 5 = 0.4 mL = 40 units.

The reconstitution calculator does this both directions, and the mg to units calculator converts a milligram figure into syringe units once your concentration is set. For the water step itself, see how much bacteriostatic water to add.

Quick reference summary

• Targets: survodutide hits GLP-1 and glucagon; retatrutide hits GLP-1, glucagon, and GIP.
• Trial average loss: about 18.7% vs about 24.2%, from separate Phase 2 trials.
• Glucagon ratio: balanced dual in survodutide; one of three levers in retatrutide.
• Liver angle: survodutide studied directly for MASH and MASLD; retatrutide reports liver fat as a secondary readout.
• Math: identical once reconstituted, only concentration changes the units.

For tracking schedules, doses, and vial concentrations in one place, the Stackr app keeps the running log. See the full disclaimer before using any figure here.